NT79: A Novel Neurotensin Receptor Agonist with Selective Behavioral Effects

被引：0
|
作者：
Boules, Mona M. [1 ]
Liang, Yanqi [1 ]
Oliveros, Alfredo [1 ]
Fauq, Irfan [1 ]
Wilson, Mina [1 ]
Khaniyev, Shaheen [1 ]
Williams, Katrina [1 ]
Barbut, Denise [2 ]
Richelson, Elliott [1 ]
机构：
[1] Mayo Clin, Jacksonville, FL 32224 USA
[2] Sarentis Therapeut Inc, Res, New York, NY USA
来源：
BIOLOGICAL PSYCHIATRY | 2009年 / 65卷 / 08期
关键词：
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
232
引用
收藏
页码：71S / 71S
页数：1
相关论文
共 50 条
  • [31] Behavioral effects of the novel cannabinoid full agonist AM 411
    McLaughlin, PJ
    Lu, D
    Winston, KM
    Thakur, G
    Swezey, LA
    Makriyannis, A
    Salamone, JD
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2005, 81 (01) : 78 - 88
  • [32] Oral administration of ABS201, a novel neurotensin-1 receptor agonist, produces preclinical antipsychotic-like effects
    Feifel, David
    Dix, Tom
    Melendez, Gilia
    Brower, Justin
    Sasaki, Dean
    Shilling, Paul
    NEUROPSYCHOPHARMACOLOGY, 2006, 31 : S120 - S121
  • [33] Characterization and assignment of uniformly labeled NT(8-13) at the agonist binding site of the G-protein coupled neurotensin receptor
    Williamson, PTF
    Bains, S
    Chung, C
    Cooke, R
    Meier, BH
    Watts, A
    PERSPECTIVES ON SOLID STATE NMR IN BIOLOGY, 2001, 1 : 191 - 201
  • [34] Effects of a selective glucocorticoid receptor agonist on osteoblastic and osteoclastic cells
    Rauner, M.
    Finger, S.
    Goettsch, C.
    Benad, R.
    Hofbauer, L. C.
    BONE, 2009, 44 (02) : S312 - S312
  • [35] Evaluation of the Selective Glucocorticoid Receptor Agonist Compound A for Ototoxic Effects
    Honeder, Clemens
    Engleder, Elisabeth
    Schoepper, Hanna
    Krause, Markus
    Landegger, Lukas David
    Plasenzotti, Roberto
    Gabor, Franz
    Gstoettner, Wolfgang
    Arnoldner, Christoph
    LARYNGOSCOPE, 2015, 125 (04): : E149 - E155
  • [36] Delayed Administration of a Pan-Selective Sigma Receptor Agonist after MCAO: Effects on Neural Injury and Behavioral Recovery
    Leonardo, Christopher C.
    Ajmo, Craig T., Jr.
    Collier, Lisa A.
    Green, Suzanne M.
    Cuevas, Javier
    Willing, Alison E.
    Pennyipacker, Keith R.
    STROKE, 2009, 40 (04) : E133 - E133
  • [37] Anorectic effects of human urocortin ii, a novel, selective type 2 CRF receptor agonist, in the rat
    Inoue, K
    Valdez, GR
    Reinhardt, LE
    Tabarin, A
    Rivier, J
    Vale, WW
    Koob, GF
    Zorrilla, EP
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2002, 17 : S158 - S158
  • [38] Antidepressant effects of pramipexole, a novel dopamine receptor agonist
    Maj, J
    Rogoz, Z
    Skuza, G
    Kolodziejczyk, K
    JOURNAL OF NEURAL TRANSMISSION, 1997, 104 (4-5) : 525 - 533
  • [39] The behavioural effects of pramipexole, a novel dopamine receptor agonist
    Maj, J
    Rogoz, Z
    Skuza, G
    Kolodziejczyk, K
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 324 (01) : 31 - 37
  • [40] Regulatory effects of a novel liver X receptor agonist
    Kratzer, A.
    Ebner, B.
    Becker, T.
    Calayir, E.
    Levak-Frank, S.
    Uray, G.
    Kostner, G. M.
    Kratky, D.
    CHEMISTRY AND PHYSICS OF LIPIDS, 2006, 143 (1-2) : 88 - 88
12345